Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. by Leapman, Michael S et al.
UCSF
UC San Francisco Previously Published Works
Title
Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 
2 for prediction of high grade and high stage prostate cancer.
Permalink
https://escholarship.org/uc/item/2sx369q8
Journal
Radiologia Brasileira, 50(5)
ISSN
0100-3984
Authors
Leapman, Michael
Wang, Zhen
Behr, Spencer
et al.
Publication Date
2017-09-01
DOI
10.1590/0100-3984.2016.0117
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Leapman MS et al. / PI-RADS v2 plus MRI spectroscopy
299Radiol Bras. 2017 Set/Out;50(5):299–307
Original rticle
Impact of the integration of proton magnetic resonance 
imaging spectroscopy to PI-RADS 2 for prediction of high 
grade and high stage prostate cancer
Impacto da incorporação da espectroscopia por ressonância magnética ao PI-RADS 2  
para a predição de câncer de próstata de alto grau e de estágio avançado
Michael S. Leapman1, Zhen J. Wang2, Spencer C. Behr2, John Kurhanewicz3, Ronald J. Zagoria2, Peter R. Carroll4, 
Antonio C. Westphalen5
Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, Westphalen AC. Impact of the integration of proton magnetic resonance imag-
ing spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiol Bras. 2017 Set/Out;50(5):299–307.
Abstract
Resumo
0100-3984 © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem http://dx.doi.org/10.1590/0100-3984.2016.0117
Objective: To compare the predictions of dominant Gleason pattern ≥ 4 or non-organ confined disease with Prostate Imaging Re-
porting and Data System (PI-RADS v2) with or without proton magnetic resonance spectroscopic imaging (1H-MRSI).
Materials and Methods: Thirty-nine men underwent 3-tesla endorectal multiparametric MRI including 1H-MRSI and prostatectomy. 
Two radiologists assigned PI-RADS v2 and 1H-MRSI scores to index lesions. Statistical analyses used logistic regressions, receiver 
operating characteristic (ROC) curves, and 2x2 tables for diagnostic accuracies.
Results: The sensitivity and specificity of 1H-MRSI and PI-RADS v2 for high-grade prostate cancer (PCa) were 85.7% (57.1%) and 
92.9% (100%), and 56% (68.0%) and 24.0% (24.0%). The sensitivity and specificity of 1H-MRSI and PI-RADS v2 for extra-prostatic 
extension (EPE) were 64.0% (40%) and 20.0% (48%), and 50.0% (57.1%) and 71.4% (64.3%). The area under the ROC curves (AUC) 
for prediction of high-grade prostate cancer were 0.65 and 0.61 for PI-RADS v2 and 0.72 and 0.70 when combined with 1H-MRSI 
(readers 1 and 2, p = 0.04 and 0.21). For prediction of EPE the AUC were 0.54 and 0.60 for PI-RADS v2 and 0.55 and 0.61 when 
combined with 1H-MRSI (p > 0.05).
Conclusion: 1H-MRSI might improve the discrimination of high-grade prostate cancer when combined to PI-RADS v2, particularly for 
PI-RADS v2 score 4 lesions, but it does not affect the prediction of EPE.
Keywords: MRI; Spectroscopy; Diagnosis; Prostate cancer; Prostatectomy.
Objetivo: Comparar as predições de tumor com padrão 4 de Gleason dominante ou de tumor com extensão extraprostática utili-
zando o sistema Prostate Imaging Reporting and Data System (PI-RADS v2), combinado ou não a espectroscopia por ressonância 
magnética (1H-ERM).
Materiais e Métodos: Trinta e nove pacientes submeteram-se a RM de 3 tesla com bobina endorretal, incluindo 1H-ERM, e pros-
tatectomia. Dois radiologistas classificaram as principais lesões identificadas em cada caso utilizando PI-RADS v2 e escores de 
1H-ERM. As análises estatísticas incluíram regressões logísticas, curvas receiver operating characteristic (ROC) e tabelas 2x2 para 
acurácia diagnóstica.
Resultados: A sensibilidade e a especificidade da 1H-ERM e do PI-RADS v2 para a detecção de câncer de próstata de alto grau 
foram 85,7% (57,1%) e 92,9% (100%), e 56% (68%) e 24% (24%). A sensibilidade e a especificidade da 1H-ERM e do PI-RADS v2 
para a detecção de extensão extraprostática (EEP) foram 64,0% (40%) e 20% (48%), e 50% (57,1%) e 71,4% (64,3%). As áreas das 
curvas ROC para a predição de câncer de alto grau foram 0,65 e 0,61 para PI-RADS v2 e 0,72 e 0,70 quando combinado com 1H-
-ERM (radiologistas 1 e 2, p = 0.04 e 0.21). Para a predição de EEP, as áreas das curvas ROC foram 0,54 e 0,60 para PI-RADS v2 
e 0,55 e 0,61 quando combinado com 1H-ERM (p > 0.05).
Conclusão: É possível que a 1H-ERM melhore a predição de câncer de alto grau quando combinada ao PI-RADS v2, em particular 
para lesões que recebem um escore PI-RADS v2 4; entretanto, ela não afeta a predição de EEP.
Unitermos: Espectroscopia; Diagnóstico; Câncer de próstata; Prostatectomia.
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INTRODUCTION
Prostate cancer (PCa) is diagnosed in approximately 
230,000 men in the United States each year(1), the ma-
jority of whom will possess favorable risk disease and 
in whom conservative approaches including active sur-
veillance may be prudent(2). Multiparametric magnetic 
resonance imaging (mpMRI) of the prostate has gained 
considerable utilization in the setting of newly diagnosed 
disease to identify occult, higher-grade or stage elements 
missed by conventional biopsy(3,4). Moreover, when cou-
pled with real time ultrasonography, fusion mpMRI bi-
opsy has demonstrated superior PCa detection rates com-
pared with traditional template guided biopsy(5).
With growing integration of mpMRI as an adjunct 
diagnostic modality, the need to standardize acquisition 
protocols and study reporting is evident as it may facili-
tate benchmarks for consistency in both clinical care 
and research settings alike(6). The American College of 
Radiology, the AdMeTech Foundation, and the European 
Society of Urogenital Radiology have partnered and re-
cently presented a new version of the Prostate Imaging 
Reporting and Data System (PI-RADS v2), which inte-
grates results of T2-weighted (T2W), high b-value diffu-
sion-weighted image (DWI), and dynamic contrast en-
hanced (DCE) MRI(7). Proton MR spectroscopic imaging 
(1H-MRSI), previously an optional tool, was not included 
in the current version of the document. 1H-MRSI has, 
though, been recognized as a useful non-invasive method 
for evaluating metabolic characteristics of prostatic le-
sions, yielding identifiable signatures that may allow for 
the discrimination of high-grade tumors(8). However, 1H-
MRSI is susceptible to false positive related to choline 
contamination from the seminal vesicles or urethra(9), or 
by prostatitis(10). Furthermore, the ACRIN 6659 study 
that was published by Weinreb et al. found no added ben-
efit for 1H-MRSI compared with T2W alone to localize 
PCa to the gland sextant(11).
In this context, we sought to compare the diagnostic 
performance of PI-RADS v2 with or without 1H-MRSI 
for predicting PCa with dominant Gleason pattern ≥ 4 or 
non-organ confined disease at the time of surgery.
MATERIALS AND METHODS
The Institutional Review Board approved this ret-
rospective single center study. Informed consent was 
prospectively obtained from all patients authorizing the 
use of clinical data in future studies. Consecutive sub-
jects were identified through searches of our Urological 
Oncological Database, Prostate MR Imaging Database, 
and electronic medical records. Inclusion criteria: biopsy-
proven PCa; 3-tesla endorectal prostate mpMRI, includ-
ing 1H-MRSI; radical prostatectomy within six months of 
imaging; no treatments between imaging and surgery.
Forty patients seen between January 2013 and De-
cember 2014 fulfilled these criteria, but one was excluded 
because of a hip replacement that distorted the 1H-MRSI 
data. Therefore, 39 men formed the study population. Pa-
tients were clinically risk stratified using the Cancer of 
the Prostate Risk Assessment score (CAPRA)(12). CAPRA 
is an easy to calculate validated nomogram that predicts 
outcomes across multiple treatment approaches and it 
predicts an individual’s likelihood of metastasis, cancer-
specific mortality, and overall mortality. The score is cal-
culated using points assigned to: age at diagnosis, PSA 
at diagnosis, Gleason score of the biopsy, clinical stage 
and percent of biopsy cores involved with cancer. Three 
categories were assigned: low (scores 0–2), intermediate 
(scores 3–5), and high risk (scores 6–10).
MRI technique
Scans were acquired on a 3-tesla scanner (GE Health-
care, Waukesha, WI, USA) using the body coil for excita-
tion and an endorectal coil (E-Coil; Medrad, Pittsburgh, 
PA, USA) filled with perfluorocarbon (Flutech_T14 TM; 
F2 Chemicals, UK) and a phased-array coil for reception. 
Images were post-processed to compensate for the recep-
tion profile of the endorectal coil(13).
The protocol included:
– Oblique axial T2W high-resolution 2D FSE MR im-
ages (thickness/gap = 3 mm/0 mm; TR/TE = 5600–7400 
ms/96–114 ms; ETL = 16; FOV = 180 mm × 180 mm; 
reconstructed matrix 512 × 512; frequency direction AP, 
1 NEX). Acquisition time = 4 min 1 s.
– Axial CUBE T2W 3D FSE MR images (thickness/
gap = 1.6 mm/0 mm; TR/TE = 2400 ms/142.4 ms; ETL 
= 90; FOV = 180 mm × 180 mm; 512 × 512 interpolated 
matrix in-plane and 2-fold along the craniocaudal axis; 
frequency direction AP, 2 NEX; flip angle = 90°; receiver 
bandwidth = 90.91 kHz). Coronal and sagittal reformats 
were generated. Acquisition time = 4 min 42 s.
– Two 2D single-shot EPI SE high b-value DWI ac-
quisitions (thickness/gap = 3 mm/0 mm; TR/TE = 4725 
ms/minimum; FOV = 180 mm × 180 mm; 128 × 64; b-
values 0 and 600 and 0 and 1350). Acquisition times = 
3 min 52 s and 4 min 29 s. Two ADC maps were recon-
structed from each acquisition.
– Oblique axial T1-weighted 3D spoiled gradient 
echo dynamically contrast enhanced MR images (thick-
ness/gap = 3 mm/0 mm; TR/TE = minimum/minimum; 
FOV = 260 mm × 260 mm; 192 × 128; 1 NEX; gadopen-
tetate dimeglumine, 0.1 mmol/kg of body weight, at a rate 
of 3 cm3/s using a power injector, followed by a 20 cm3 
saline bolus at the same rate, 5 min acquisition, temporal 
resolution = 10 s). Acquisition time = 4 min 58 s.
– 3D 1H-MRSI using a water and lipid-suppressed 
double-spin-echo point resolved spectroscopy sequence 
(MLEV-PRESS) with spectral-spatial pulses for the two 
180° excitation pulses, and outer-voxel saturation pulses 
(thickness/gap = 3 mm/0 mm; TR/TE = 2000 ms/85 ms; 
NEX = 1; phase encoding steps = 16 × 10 × 8; FOV = 
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86 × 54 × 43 mm3 yielding a nominal spatial resolution 
of 0.16 cm3). A PRESS volume was selected using the 
oblique axial T2W images that incorporated the entire 
prostate while minimizing inclusion of the rectum and 
peri-prostatic lipids. The PRESS volume was shimmed 
using an automated phase mapping algorithm, followed 
by manual shimming of the x, y and z gradients until a 
water line-width of ≤ 12 Hz was obtained. An interleaved 
flyback echo-planar spectroscopic readout with a spectral 
bandwidth of 1012 Hz was used in the left-right dimen-
sion. Acquisition time = 7 min 50 s.
The 1H-MRSI data were processed using custom pro-
cessing software(14). The raw data acquired with the mod-
ified PRESS incorporating the flyback echo-planar read-
out trajectory were reordered as previously described(15) 
and processed in the same manner as the conventional 
4D 1H-MRSI dataset(14). The spectral data were apodized 
with a 2-Hz Lorentzian function in the frequency domain, 
with no filtering in the spatial dimensions. Data were 
Fourier transformed in the time domain and in three spa-
tial domains. Spectral phase, baseline, and frequency cor-
rections were iteratively made and metabolite peak areas 
calculated as previously described(14). The 3D 1H-MRSI 
spectral arrays and associated metabolite peak area ratios 
were overlaid on the corresponding transverse T2W im-
ages using the open-source spectral processing package 
SIVIC.
– Axial T1-weighted FGRE MR images (thickness/
gap = 4.2 mm/0 mm; TR/TE = 5.06 ms/2.46 ms; FOV = 
240 mm × 240 mm; 192 × 128; NEX = 1). Acquisition 
time = 2 min 45 s.
Image interpretation
Two radiologists (8 and 5 years of experience with 
1H-MRSI and 2 years of experience with PI-RADS v2, 
i.e. since its initial publication), unaware of the clinical 
and pathologic data, independently reviewed all scans on 
a PACS workstation (Impax; Agfa, Mortsel, Belgium) in 
a single session. To mimic clinical practice, the radiolo-
gist could review the T2W, DWI, and DCE sequences in 
any order, alone or in conjunction. The radiologists had 
no access to 1H-MRSI images at this stage. Up to four 
suspicious foci were identified and PI-RADS v2 scores as-
signed to each (Table 1)(7).
Next the radiologists reviewed the 3D spectral arrays 
to assign a 1H-MRSI score to all suspicious lesions previ-
ously assigned a PI-RADS v2 score, i.e. lesions that re-
ceived a PI-RADS v2 score ranging from 3 to 5. All usable 
voxels were scored using the five-point scale based on the 
area ratio of the citrate and choline peaks (Table 1). Fig-
ure 1 shows a representative case.
Surgical technique and histologic evaluation
Experienced urologists performed all radical prosta-
tectomies. Pelvic lymph node dissection was performed 
based on pre-operative surgical risk. Prostatectomy speci-
mens were marked with ink and fixed overnight in 10% 
buffered formalin. The glands were sectioned using 
whole-mount histology at 3 mm intervals in a plane per-
pendicular to the prostatic urethra. Experienced academic 
pathologists, unaware of imaging findings, reviewed the 
histological slides in all cases. The size, location, and 
Gleason score of all cancer foci seen in the prostate, and 
the presence, location, and extent of extra-prostatic dis-
ease were recorded.
Statistical analysis
The primary outcomes were the predictions of high-
grade PCa, defined as Gleason score ≥ 4+3, and high-
stage disease, defined as extra-prostatic extension (EPE) 
(≥ T3A) at radical prostatectomy on a per patient basis. 
In the event of multiple lesions, only the index lesion was 
considered for analyses. The index lesion was defined as 
the lesion with the highest overall PI-RADS score. If two 
or more lesions received the same score, the index lesion 
was the one associated with clear EPE. If none of the le-
sions demonstrated EPE, the index lesion was the largest 
one. We assessed the sensitivity, specificity, negative pre-
dictive value (NPV), positive predictive value (PPV), and 
accuracy of the overall PI-RADS v2 score and 1H-MRSI 
score assigned to suspicious lesions for the detection of 
these outcomes. For high-grade disease, the overall PI-
RADS v2 scores 1 to 3 were considered a negative re-
sult. For non-organ confined PCa, the overall PI-RADS 
v2 scores 1 to 4 were considered a negative result. This 
was because the presence of EPE on mpMRI determines 
an overall PI-RADS v2 score of 5. For both analyses, 1H-
MRSI was dichotomized as negative (score ≤ 3) or posi-
tive (score 4 or 5).
We compared the areas under the receiver operating 
characteristic (ROC) curve of univariate logistic regres-
sion models that included the overall PI-RADS v2 score 
or 1H-MRSI score; and those to the area under the ROC 
curve derived from the multivariate models that included 
the overall PI-RADS v2 and 1H-MRSI scores. As men-
tioned above, if more than one lesion was suspected on 
mpMRI, only the index lesion was utilized in the analyses.
Interobserver agreement of overall PI-RADS v2 and 
1H-MRSI scores were calculated utilizing a weighted kappa 
score (weights = 1 / 1 - 1 / 0.25 - 0.25 - 1 / 0 - 0 - 0.75 - 1 
/ 0 - 0 - 0.5 - 0.75 - 1).
All analyses were performed using Stata version 13.1 
(College Station, TX). P values < 0.05 were considered 
statistically significant.
RESULTS
The median age was 65 years (interquartile range 
(IQR), 11). The median PSA at diagnosis was 6.8 ng/mL 
(IQR, 5.1). CAPRA classified 13 men (33.3%) with low, 
21 (53.9%) with intermediate, and 5 (12.8%) with high 
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clinical risk. Thirty-seven men (94.8%) had clinically 
organ-confined disease at diagnosis; and 28 (71.8%) had 
biopsy Gleason score ≤ 3+4. The complete clinical, de-
mographic and pathologic characteristics are presented 
in Table 2.
At prostatectomy, 5 men (12.8%) had Gleason score 
3+3, 20 (51.3%) had Gleason score 3+4, 12 had Gleason 
score 4+3 (30.8%), 1 (2.6%) had Gleason score 4+4, and 
1 (2.6%) had Gleason score 5+4. Disease was organ-con-
fined (T2C or less) in 19 (48.7%). Twenty men (51.3%) 
had extra-prostatic extension.
Table 1 reports the complete distribution of imaging 
findings for both readers; the weighted kappa of the over-
all PI-RADS v2 and of 1H-MRSI scores were 0.62 (95% 
confidence interval: 0.47–0.81; 88.8% agreement) and 
0.46 (95% confidence interval: 0.22–0.70; 76.9% agree-
ment), respectively.
The specificity of 1H-MRSI (assigned to a suspicious 
lesion) to predict Gleason pattern ≥ 4+3 was higher than 
the specificity of the overall PI-RADS v2 score (56.0%, 
reader 1, and 68.0%, reader 2, versus 24%, both readers). 
For the detection of stage ≥ T3a, the use of 1H-MRSI 
scores to further characterize suspicious lesions led, for 
reader 1, to an increase in sensitivity (64% versus 20%) 
associated with a decrease in specificity (50% versus 
71.4%). No clear differences were seen for reader 2. The 
performance characteristics are outlined in Table 3.
Table 4 details the AUCs for the prediction of Glea-
son pattern ≥ 4+3 and extraprostatic disease. These re-
sults are also illustrated in Figure 2.
Table 1—Distribution of imaging findings according to PI-RADS v2 criteria and 1H-MRSI.
Sequence
T2W – Peripheral zone
1 – Uniform hyperintense signal intensity (normal)
2 – Linear or wedge-shaped hypointensity/diffuse mild hypointensity, usually indistinct margin
3 – Heterogenous signal intensity or non-circumscribed rounded, moderate hypointensity
4 – Circumscribed, homogenous moderate hypointense focus/mass confined to prostate and < 1.5 cm in greatest dimension
5 – As above, but ≥ 1.5 cm in greatest dimension or definitive extra-prostatic extension/invasive behavior
T2W – Transition zone
1 – Homogeneous intermediate signal intensity (normal)
2 – Circumscribed hypointense or heterogeneous encapsulated nodule(s) (benign prostatic hyperplasia)
3 – Heterogeneous signal intensity with obscured margins; includes others that do not qualify as 2, 4, or 5
4 – Lenticular or non-circumscribed, homogeneous, moderately hypointense, and < 1.5 cm in greatest dimension
5 – As above, but ≥ 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior
DWI
1 – No abnormality
2 – Indistinct hypointensity on ADC
3 – Focal mildly/moderately hypointense on ADC and isointense/mildly hyperintense on high b-value DWI
4 – Focal markedly hypointense on ADC and markedly hyperintense on high b-value DWI; < 1.5 cm in greatest dimension 
5 – As above, but ≥ 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior
DCE
(–) No early enhancement; or diffuse enhancement not corresponding to a focal finding on T2 and/or DWI; or focal enhance-
ment corresponding to a lesion demonstrating features of benign prostatic hyperplasia on T2WI
(+) focal, and; earlier than contemporaneously with enhancement of adjacent normal prostate tissue, and; corresponds to 
suspicious finding on T2W and/or DWI
Overall score
1 – Very low (clinically significant cancer is highly unlikely to be present)
2 – Low (clinically significant cancer is unlikely to be present)
3 – Intermediate (the presence of clinically significant cancer is equivocal)
4 – High (clinically significant cancer is likely to be present)
5 – Very high (clinically significant cancer is highly likely to be present)
1H MRSI
1 – Citrate:choline ratio ≥ 2
2 – Citrate:choline ratio 1–2
3 – Choline=citrate
4 – Choline:citrate ratio 1–2
5 – Choline:citrate ratio ≥ 2
N
0
1
11
14
3
0
0
1
2
5
2
0
4
23
10
11
28
0
2
5
23
9
3
5
8
22
1
N
0
0
5
11
10
0
0
1
1
8
3
0
8
12
16
14
25
0
3
3
16
17
3
8
12
13
3
Reader 1 Reader 2
(%)
(0)
(3.5)
(37.9)
(48.3)
(10.3)
(0)
(0)
(12.5)
(25.0)
(62.5)
(5.1)
(0)
(10.3)
(59.0)
(25.6)
(28.2)
(71.8)
(0)
(5.1)
(12.8)
(59.0)
(23.1)
(7.7)
(12.8)
(20.5)
(56.4)
(2.6)
(%)
(0)
(0)
(19.3)
(42.3)
(38.5)
(0)
(0)
(10.0)
(10.0)
(80.0)
(7.7)
(0)
(20.5)
(30.8)
(41.0)
(35.9)
(64.1)
(0)
(7.7)
(7.7)
(41.0)
(43.6)
(7.7)
(20.5)
(30.8)
(33.3)
(7.7)
N, number of patients.
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Figure 1. 73-year-old man with Gleason 4+3 prostate cancer in the right posterior peripheral zone on radical prostatectomy, corresponding to the findings on 
imaging (arrows). Reader 1 (and reader 2) characterized the lesion as T2 = 3 (4), DWI = 4 (4), DCE = negative (positive), and overall PI-RADS v2 score = 4 (4). Both 
readers assigned it a MRSI score of 4 (outlined voxels).
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Analysis of the shape of the ROC curves shows that 
the addition of 1H-MRSI to PI-RADS v2 improves the 
prediction of high-grade PCa when lesions are charac-
terized as PI-RADS v2 score 4. There were no statisti-
cally significant differences between the AUC of overall 
PI-RADS v2 (0.65, reader 1; and 0.61, reader 2) and 
1H-MRSI (0.75, reader 1; and 0.70, reader 2) for either 
reader. The AUC of overall PI-RADS v2 combined with 
1H-MRSI was significantly higher than the AUC of overall 
PI-RADS v2 alone for reader 1 (0.77; p = 0.04), but not 
for reader 2 (0.70; p = 0.21).
For the discrimination of stage ≥ T3a, there were no 
statistically significant differences between the AUC of 
overall PI-RADS v2 (0.54, reader 1; and 0.60, reader 2), 
1H-MRSI (0.61, reader 1; and 0.54, reader 2), and their 
combination (0.55, reader 1; and 0.61, reader 2) for ei-
ther reader.
DISCUSSION
Our results suggest that the addition of 1H-MRSI to 
PI-RADS v2 might improve the detection of PCa with 
Gleason pattern ≥ 4+3, in particular of PI-RADS v2 score 
4 lesions; however, it does not seem to increase the detec-
tion of high stage (≥ T3a) disease.
Different from its initial version, PI-RADS v2 does not 
include 1H-MRSI. Yet, the PI-RADS Steering Committee 
encourages “the continued development of promising 
MRI methodologies”, including 1H-MRSI(16), and state 
that these technologies will be considered for inclusion 
in future versions, pending new data. While the PI-RADS 
v2 document does not provide specific reasons for not in-
cluding 1H-MRSI, it is known that it is a complex tech-
nique with limited acceptance outside specialized centers 
due to its long acquisition time, need for local expertise, 
and general reliance on endorectal coil imaging. Yet, 1H-
MRSI warrants continue attention; new hardware and 
software developments may make it more manageable.
Table 2—Baseline population characteristics.
Variable
Age at diagnosis, median (IQR, range)
PSA, ng/ml, median (IQR, range)
PSA density, median (IQR, range)
Clinical stage (digital rectal examination), N (%)
T1c
T2a
T2b
T3a
T3b
Diagnosis biopsy Gleason grade, N (%)
3+3
3+4
4+3
4+4
5+4
5+5
Number of diagnostic cores taken, median (IQR, 
range)
Percentage of positive diagnostic cores, median 
(IQR, range)
CAPRA score, %
0–2 (low risk)
3–5 (intermediate risk)
6–10 (high risk)
Statistic
65 (11, 45–75)
6.8 (5.1, 1.62–16)
0.20 (0.15, 0.06–0.65)
11 (28.2)
25 (64.1)
1 (2.6)
1 (2.6)
1 (2.6)
9 (23.1)
19 (48.7)
8 (20.5)
1 (2.6)
1 (2.6)
1 (2.6)
15 (5, 6–24)
25 (29, 8–50)
13 (33.3)
21 (53.9)
5 (12.8)
IQR, interquartile range; PSA, prostate specific antigen; N, number of patients.
Table 3—Diagnostic test characteristics of PI-RADS v2 and 1H-MRSI for the 
identification of high grade prostate cancer (dominant Gleason pattern ≥ 4) 
and extraprostatic disease at radical prostatectomy.
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
High grade prostate cancer (dominant Gleason pattern ≥ 4)
Reader 1
Overall PI-RADS 2
1H MRSI
Overall PI-RADS 2
1H MRSI
Overall PI-RADS 2
1H MRSI
Overall PI-RADS 2
1H MRSI
92.9
(66.1–99.8)
85.7
(57.2–98.2)
100.0
(76.8–100)
57.1
(28.9–82.3)
20.0
(6.8–40.7)
64.0
(42.5–82.0)
48.0
(27.8–68.7)
40.0
(21.1–61.3)
24.0
(9.4–45.1)
56.0
(34.9–75.6)
24.0
(9.4–45.1)
68.0
(46.5–85.1)
71.4
(41.9–91.6)
50.0
(23.0–77.0)
64.3
(35.1–87.2)
57.1
(28.9–82.3)
40.6
(23.7–59.4)
52.2
(30.6–73.2)
42.4
(25.5–60.8)
50.0
(24.7–75.3)
55.6
(21.2–86.3)
69.6
(47.1–86.8)
70.6
(44.0–89.7)
62.5
(35.4–84.8)
85.7
(42.1–99.6)
87.5
(61.7–98.4)
100.0
(54.1–100)
73.9
(51.6–89.8)
33.3
(17.3–52.8)
43.8
(19.8–70.1)
40.9
(20.7–63.6)
34.8
(16.4–57.3)
Reader 2
Extraprostatic disease (stage ≥ T3a)
Reader 1
Reader 2
95% CI, 95% confidence interval.
Table 4—Performance of PI-RADS v2 and 1H-MRSI, alone and combined, for the 
discrimination of high-grade prostate cancer (dominant Gleason pattern ≥ 4) 
and extraprostatic disease at radical prostatectomy.
Reader 1 Reader 2
AUC
0.65
0.75
0.77
0.54
0.61
0.55
95% CI
0.49-0.81
0.62-0.87
0.63-0.91
0.34-0.73
0.43-0.79
0.34-0.76
AUC
0.61
0.70
0.70
0.60
0.54
0.61
95% CI
0.45-0.77
0.55-0.86
0.53-0.86
0.42-0.78
0.36-0.73
0.43-0.80
Dominant Gleason pattern 4 or higher outcome
Pathological stage T3a or higher outcome
Model variables
Overall PI-RADS 2
1H MRSI
Overall PI-RADS 2 + 1H MRSI
Overall PI-RADS 2
1H MRSI
Overall PI-RADS 2 + 1H MRSI
95% CI, 95% confidence interval.
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Based on previous studies, 1H-MRSI improves tumor 
localization(17,18), volume estimation(19,20), staging(21), tis-
sue characterization(22), and identification of recurrent 
disease after therapy(23,24). A multicenter study showed 
that positive MR spectroscopy findings are likely to re-
flect higher tumor grade and/or volume(25). These stud-
ies, though, do have limitations, and there are, also, those 
with less encouraging results; the ACRIN study published 
in 2009, for example, showed no difference of accuracy 
when comparing combined T2W and 1H-MRSI and T2W 
alone(11).
Our results show that the overall PI-RADS v2 score 
is very sensitive to detect Gleason pattern ≥ 4+3, but its 
specificity is very low. This suggests PI-RADS v2 is a good 
option to detect the disease, but not necessarily to char-
acterize it. The use of 1H-MRSI, however, led to a 50% in-
crease in specificity, and might at least in some cases help 
to identify men with high-grade PCa. Our results showed 
this is particularly true when a lesion receives a PI-RADS 
v2 score of 4. These results are aligned to those of Giusti 
et al., who showed that metabolic ratios correlate with 
Gleason scores(26), and they are similar to those of a meta-
analysis in which 1H-MRSI had a higher specificity than 
T2W and increased the specificity of the combination of 
T2W and DWI(18). While the comparison of overall AUCs 
(i.e. summary of data for all lesions) found an improve-
ment of discrimination between men with and without 
PCa Gleason pattern ≥ 4+3 using the combined PI-RADS 
v2 and 1H-MRSI for one reader only, the assessment of 
the shape of the curves shows a clear separation between 
the lines of the ROC curves of PI-RADS v2 alone and 
PI-RADS v2 combined with1H-MRSI at the segment that 
includes only PI-RADS v2 score 4 lesions for both read-
ers. It is possible that this discrepancy in results is due to 
differences in readers’ experience. 1H-MRSI is a complex 
technique and interpretation can be challenging. It is im-
portant to make note of this fact, as these same challeng-
es are likely to be found at other sites that lack radiologist 
with experience with 1H-MRSI.
The metabolic nature of 1H-MRSI might explain why 
it did improve the detection of EPE, as EPE is typically 
detected on anatomical images. The overall PI-RADS v2 
score, however, does include an anatomical assessment. 
Furthermore, both readers assigned an overall PI-RADS 
Figure 2. ROC curves for the prediction of pathological Gleason pattern 4 or higher disease (A,B) by the overall PI-RADS v2 score alone and PI-RADS v2 combined 
with 1H-MRSI. Images C and D depict the ROC curves for the prediction of non-organ confined disease (stage T3a or greater) by the same models.
A B
C D
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score of 4 or 5 to more than 80% of these suspicious le-
sions, and an overall PI-RADS v2 score of 5, at least in some 
instances, characterizes definite EPE(16). An increase in 
specificity after utilizing 1H-MRSI might, therefore, not 
have been expected. Similarly, because 1H-MRSI was ap-
plied after the detection of a suspicious lesion using PI-
RADS v2, its sensitivity is a direct reflection of this initial 
detection. Accordingly, it would be expected that positive 
1H-MRSI results would have a greater impact on lower 
overall PI-RADS v2 scores. In this study we opted for ana-
lyzing only the index lesion, less than 20% of which re-
ceived a score of 3, likely explaining the lack of benefit of 
1H-MRSI. It remains, thus, unknown if 1H-MRSI would 
have affected cases presenting with these indeterminate 
lesions.
We did not find other studies evaluating the incorpo-
ration 1H-MRSI to PI-RADS v2, but a few authors tested 
it with its previous version with various results. The stud-
ies of Khalifa et al.(27) and Panebianco et al.(28) suggested 
1H-MRSI improved characterization of PCa and support 
our results. Yet, the results of Platzek et al.(29) and, more 
recently, Polanec et al.(30) found that 1H-MRSI did not 
increase the detection and nor improved the grading of 
PCa. While several possible explanations exist for these 
discrepancies, the exercise of explaining them is likely not 
warranted, as the first version of PI-RADS is quite differ-
ent from PI-RADS v2 and should no longer be utilized. 
More important, perhaps, is to recognize that consider-
able interest exists in optimizing the identification high 
grade or stage disease among men with clinically localized 
PCa as such determinations may improve management 
decisions. And that other imaging techniques, including 
1H-MRSI, may be helpful.
This study has limitations. First, this was a retro-
spective study with the limitations inherent to this type 
of design. The population studied was highly selected 
and included only men who had endorectal mpMRI and 
radical prostatectomy. We, therefore, probably incurred 
selection bias and our patients may not fully represent 
all men with PCa. This is illustrated by the fact most of 
our lesions were characterized as PI-RADS v2 4 and 5, as 
men with lower scores are less likely to have cancer and 
to undergo surgery. However, we considered the need for 
an adequate standard of reference more important than 
the limited generalizability. One possible option to pros-
tatectomy is MR-guided biopsy, which can be performed 
in-bore or by fusion with ultrasound. Accordingly, some 
of our results, in particular the positive and negative pre-
dictive values, do not apply to all men with suspected 
PCa nor to all men who are under active surveillance and 
typically have low-grade low-volume disease. Second, we 
examined endpoints of high-grade and/or non-organ con-
fined disease, but not more distant oncologic endpoints 
including biochemical recurrence or metastatic progres-
sion. Prospective studies with extended follow up may be 
warranted to definitively evaluate the role of 1H-MRSI in 
improved delineation of PCa outcomes. Third, PI-RADS 
was designed with the intent to improve the detection of 
tumors with Gleason score ≥ 3+4, and not ≥ 4+3 as we 
proposed. This could, perhaps, explain the low specific-
ity of PI-RADS v2 found in this study. More important, 
though, is that we may have overestimated the diagnostic 
performance of both PI-RADS v2 and 1H-MRSI due to 
spectrum bias. Spectrum bias refers to the fact that it is 
usually easier to detect advanced disease than early-stage 
disease, as subtle abnormalities can be hard to distinguish 
from normal findings. This typically leads to a higher di-
agnostic accuracy when a study includes in a population 
with advanced disease than when the subjects have less 
severe disease. We opted for characterizing as high-grade 
tumors only tumors with Gleason score ≥ 4+3 because 
many institutions consider men with Gleason 3+4 as can-
didates for active surveillance, while a Gleason score ≥ 
4+3 is universally considered an indication for definitive 
therapy.
In summary, 1H-MRSI might improve the discrimi-
nation of pathological Gleason score ≥ 4+3 when added 
to the PI-RADS v2, in particular for lesions that receive 
a score of 4, but it does not affect the prediction of PCa 
stage ≥ T3a.
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